thiorphan has been researched along with Diabetic Nephropathies in 1 studies
Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Renoprotective potential of thiorphan (NEPi)/telmisartan (ARB) and thiorphan/Dize (ACE2 activator) combination therapies against the development of DN is primarily attributed to normalisation of RAS and NPS components and inhibition of pathological signalling related to inflammation, fibrosis, and apoptosis." | 3.91 | Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy. ( Gaikwad, AB; Malek, V; Sankrityayan, H; Sharma, N, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malek, V | 1 |
| Sharma, N | 1 |
| Sankrityayan, H | 1 |
| Gaikwad, AB | 1 |
1 other study available for thiorphan and Diabetic Nephropathies
| Article | Year |
|---|---|
Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme 2; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Nephr | 2019 |